Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 20160032)

1.

Ethyl pyruvate administration inhibits hepatic tumor growth.

Liang X, Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA, Zeh HJ, Beer-Stolz D, Lotze MT, de Vera ME.

J Leukoc Biol. 2009 Sep;86(3):599-607. doi: 10.1189/jlb.0908578.

2.

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP.

J Med Chem. 2009 Dec 10;52(23):7364-7. doi: 10.1021/jm900518f.

PMID:
19507862
3.

The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity.

Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L.

J Immunol. 2009 Jun 15;182(12):7509-17. doi: 10.4049/jimmunol.0804328.

4.

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.

Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH.

Blood. 2009 Jun 11;113(24):6102-11. doi: 10.1182/blood-2008-12-195354. Epub 2009 Apr 14.

5.

Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock.

Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, Park WS, Han J, Seo SK, Lee SY, Park YM.

J Immunol. 2009 Mar 1;182(5):3146-54. doi: 10.4049/jimmunol.0803104.

6.

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17073-8. doi: 10.1073/pnas.0806173105. Epub 2008 Oct 24.

7.

A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass.

Bennett-Guerrero E, Swaminathan M, Grigore AM, Roach GW, Aberle LG, Johnston JM, Fink MP.

J Cardiothorac Vasc Anesth. 2009 Jun;23(3):324-9. doi: 10.1053/j.jvca.2008.08.005. Epub 2008 Oct 4.

PMID:
18835526
8.

Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ.

J Med Chem. 2008 Aug 28;51(16):4968-77. doi: 10.1021/jm800512z. Epub 2008 Jul 30.

9.

Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.

Carr G, Chung MK, Mauk AG, Andersen RJ.

J Med Chem. 2008 May 8;51(9):2634-7. doi: 10.1021/jm800143h. Epub 2008 Apr 8.

PMID:
18393489
10.

Twelve immunotherapy drugs that could cure cancers.

Cheever MA.

Immunol Rev. 2008 Apr;222:357-68. doi: 10.1111/j.1600-065X.2008.00604.x. Review.

PMID:
18364014
11.

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Katz JB, Muller AJ, Prendergast GC.

Immunol Rev. 2008 Apr;222:206-21. doi: 10.1111/j.1600-065X.2008.00610.x. Review.

PMID:
18364004
12.

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ.

J Med Chem. 2008 Mar 27;51(6):1706-18. doi: 10.1021/jm7014155. Epub 2008 Mar 5. Erratum in: J Med Chem. 2008 Nov 27;51(22):7325.

13.

Immune escape as a fundamental trait of cancer: focus on IDO.

Prendergast GC.

Oncogene. 2008 Jun 26;27(28):3889-900. doi: 10.1038/onc.2008.35. Epub 2008 Mar 3. Review.

PMID:
18317452
14.

Creating immune privilege: active local suppression that benefits friends, but protects foes.

Mellor AL, Munn DH.

Nat Rev Immunol. 2008 Jan;8(1):74-80. Review. Erratum in: Nat Rev Immunol. 2008 Feb;8(2):160.

PMID:
18064049
15.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
16.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

17.

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice.

Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH.

Gene. 2007 Jul 1;396(1):203-13. Epub 2007 Apr 18. Erratum in: Gene. 2010 Oct 1;465(1-2):66.

PMID:
17499941
18.

Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy.

Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P.

Nat Med. 2007 May;13(5):579-86. Epub 2007 Apr 8.

PMID:
17417651
19.

Ethyl pyruvate: a novel anti-inflammatory agent.

Fink MP.

J Intern Med. 2007 Apr;261(4):349-62. Review.

PMID:
17391109
20.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk